Chapter 1 Methodology & Scope
1.1 Industry coverage
1.2 Market scope & definitions
1.3 Base estimates & working
1.3.1 Data collection
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data sources
1.7.1 Primary
1.7.2 Secondary
1.7.2.1 Paid sources
1.7.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Molecular diagnostics industry 3600 synopsis, 2018 - 2032
2.1.1 Business trends
2.1.2 Product trends
2.1.3 Technology trends
2.1.4 Application trends
2.1.5 End-use trends
2.1.6 Regional trends
Chapter 3 Molecular Diagnostics Industry Insights
3.1 Industry landscape, 2018 – 2032
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Technological advances and increasing awareness towards early disease diagnosis globally
3.2.1.2 Escalating demand for POC diagnostics
3.2.1.3 Increasing geriatric population
3.2.1.4 Increasing number of R&D initiatives in developing economies
3.2.1.5 Rising incidences of infectious diseases
3.2.2 Industry pitfalls & challenges
3.2.2.1 Lack of clear and uniform regulatory framework
3.2.2.2 Increasing cost of disease diagnostics
3.3 Growth potential analysis
3.3.1 By product
3.3.2 By technology
3.3.3 By application
3.3.4 By end-use
3.4 COVID-19 impact analysis
3.5 Regulatory Landscape
3.5.1 U.S.
3.5.2 Europe
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.1.1 Bio-Rad Laboratories Inc
4.1.2 F. Hoffmann-La Roche AG
4.1.3 Abbott Laboratories
4.2 Competitive dashboard, 2022
4.3 Company matrix analysis, 2022
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategic outlook matrix
Chapter 5 Molecular diagnostics Market, By Product
5.1 Key segment trends
5.2 Instruments
5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3 Reagents and kits
5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 6 Molecular Diagnostics Market, By Technology
6.1 Key segment trends
6.2 Polymerase chain reaction (PCR)
6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3 Hybridization
6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.4 Sequencing
6.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.5 Isothermal nucleic acid amplification technology (INAAT)
6.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.6 Microarrays
6.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.7 Others
6.7.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 7 Molecular Diagnostics Market, By Application
7.1 Key segment trends
7.2 Infectious disease diagnostics
7.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.2.2 COVID-19
7.2.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.2.3 HIV
7.2.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.2.4 CT/NG
7.2.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.2.5 Hepatitis B
7.2.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.2.6 Hepatitis C
7.2.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.2.7 RSV
7.2.7.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.2.8 Flu
7.2.8.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.2.9 Tuberculosis
7.2.9.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.2.10 Others
7.2.10.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.3 Oncology testing
7.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.4 Genetic disease testing
7.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.5 Others
7.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 8 Molecular Diagnostics Market, By End-use
8.1 Key segment trends
8.2 Hospitals and clinics
8.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
8.3 Diagnostic laboratories
8.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
8.4 Others
8.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 9 Molecular Diagnostics Market, By Region
Chapter 10 Company Profiles
10.1 Abbott Laboratories
10.2 Agilent Technologies Inc
10.3 Becton, Dickinson and Company
10.4 Biocartis
10.5 Biomerieux SA
10.6 Bio-Rad Laboratories Inc
10.7 Danaher Corporation
10.8 F. Hoffmann-La Roche AG
10.9 Hologic, Inc.
10.10 Illumina, Inc
10.11 Qiagen
10.12 Quidel Corporation
10.13 Siemens Healthineers AG
10.14 Sysmex Corporation
10.15 Thermo Fisher Scientific
